ERC funds development of new treatments for lung disease

by Centre for Genomic Regulation

​Today researchers at the CRG are amongst some of the world’s leading scientists in receiving funding from the European Research Council’s Advanced Grants Competition. The grant is dedicated lon...

Read more

Identified a potential target to treat lung cancer

by IRB Barcelona - Instituto de Investigación Biomédica

As an approach to personalised medicine, the work proposes the HMCES sensor of DNA damage as a target to treat some of the most aggressive types of lung tumours. The results have been published in PL...

Read more

Flomics Investment opportunity

by Flomics Biotech SL

Flomics Biotech, a startup from the Barcelona Biomedical Research Park (PRBB) operating in the genomics and liquid biopsy fields is excited to announce the launch of its seed investment round of 500.0...

Read more

CNIO researchers develop an effective strategy to induce regression in lung tumours caused by the KRAS oncogene in mice

by CNIO - Centro Nacional de Investigaciones Oncológicas

Researchers from the Experimental Oncology Group at the CNIO have achieved complete remission of 25% of lung tumours caused by the KRAS oncogene in mice by inactivating CDK4 and RAF1, two genes that a...

Read more

AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal

by Ability Pharma

The biopharmaceutical company Ability Pharmaceuticals SL announced today that the full description of the mechanism of action of ABTL0812 has been published in the prestigious Autophagy journal (impac...

Read more

DRUG TARGETS: The heat shock protein 90 inhibitor ganetespib failed to improve outcomes when added to chemotherapy in advance NSCLC (phase III GALAXY-2 trial). Samples were obtained for biomarker studies; results not yet reported

by OncoDNA

Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non–Small-Cell Lung Cancer (GALAXY-2)

Read more

LUNG CANCER: Despite early encouraging results, the EGFR inhibitor poziotinib failed to meet its primary endpoint in the phase II ZENITH20 tria

by OncoDNA

Despite early encouraging results, the EGFR inhibitor poziotinib failed to meet its primary endpoint in the phase II ZENITH20 trial. For patients with pre-treated NSCLC with EGFR exon 20 insertion mut...

Read more

New advances in the treatment of advanced lung cancer

by Fundació Bosch i Gimpera

The University of Barcelona (UB) and Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic and antifibrotic drug, for the ...

Read more

ORYZON’s iadademstat shows efficacy signs in relapsed SCLC

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, today p...

Read more

Two new grants awarded to advance potential treatments of lung cancer

by Centre for Genomic Regulation

The lab of Juan Valcárcel has been awarded a grant from the UK-based Research Charity Worldwide Cancer Research as well as a PRODUCTE grant, 2018 Knowledge Industry, from the Catalonian Government.

Read more

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients

by Ability Pharma

ABTL0812 is administered in combination with carboplatin and paclitaxel. Vall d’Hebron Institute of Oncology (VHIO, Barcelona) and Catalan Institute of Oncology (ICO, L’Hospitalet, Barcelona) lead...

Read more

Discovery of why colon cancer metastasis always follows the same invasive pattern

by Professional Newco

Roger Gomis’ team, in collaboration with another two groups in IRB Barcelona’s Oncology Programme, reveal in Nature Cell Biology the genes and mechanisms that allow liver metastasis to colonize th...

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

Low birth weight induces changes to the ...

by Fundació Clínic per a la Recerca Biomèdica

A study coordinated by researchers at BCNatal-IDIBAPS, and published b...

Photos Stream